###begin article-title 0
Atypical Haemolytic Uraemic Syndrome Associated with a Hybrid Complement Gene
###end article-title 0
###begin article-title 1
Complement Factor H Gene Abnormalities in Haemolytic Uraemic Syndrome: From Point Mutations to Hybrid Gene
###end article-title 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 164 165 164 165 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</bold>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CFH)</italic>
###xml 326 335 326 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CFHL1&#8211;5;</italic>
###xml 344 352 344 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1&#8211;5)</italic>
###xml 354 357 354 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 664 667 664 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 672 677 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 845 854 845 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
Sequence analysis of the regulators of complement activation (RCA) cluster of genes at chromosome position 1q32 shows evidence of several large genomic duplications. These duplications have resulted in a high degree of sequence identity between the gene for factor H (CFH) and the genes for the five factor H-related proteins (CFHL1-5; aliases CFHR1-5). CFH mutations have been described in association with atypical haemolytic uraemic syndrome (aHUS). The majority of the mutations are missense changes that cluster in the C-terminal region and impair the ability of factor H to regulate surface-bound C3b. Some have arisen as a result of gene conversion between CFH and CFHL1. In this study we tested the hypothesis that nonallelic homologous recombination between low-copy repeats in the RCA cluster could result in the formation of a hybrid CFH/CFHL1 gene that predisposes to the development of aHUS.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 189 198 189 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 248 251 248 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 358 361 358 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
In a family with many cases of aHUS that segregate with the RCA cluster we used cDNA analysis, gene sequencing, and Southern blotting to show that affected individuals carry a heterozygous CFH/CFHL1 hybrid gene in which exons 1-21 are derived from CFH and exons 22/23 from CFHL1. This hybrid encodes a protein product identical to a functionally significant CFH mutant (c.3572C>T, S1191L and c.3590T>C, V1197A) that has been previously described in association with aHUS.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 178 181 178 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 307 316 307 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
CFH mutation screening is recommended in all aHUS patients prior to renal transplantation because of the high risk of disease recurrence post-transplant in those known to have a CFH mutation. Because of our finding it will be necessary to implement additional screening strategies that will detect a hybrid CFH/CFHL1 gene.
###end p 7
###begin p 8
###xml 58 67 58 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
Tim Goodship and colleagues have identified a heterozygousCFH/CFHL1 hybrid gene which encodes a protein product identical to one previously described in association with atypical hemolytic uremic syndrome.
###end p 8
###begin title 9
Editors' Summary
###end title 9
###begin title 10
Background.
###end title 10
###begin p 11
###xml 95 101 <span type="species:ncbi:9606">People</span>
###xml 241 247 <span type="species:ncbi:9606">people</span>
###xml 989 995 <span type="species:ncbi:9606">people</span>
Atypical hemolytic uremic (aHUS) syndrome is a rare, chronic disease that can run in families. People with the condition are prone to developing kidney failure and high blood pressure, and are likely to have a shorter life span than healthy people. Previous work done by a group of researchers in Newcastle-on-Tyne, UK looked at the genetic underpinnings of aHUS in three families suffering from the condition. They found a region of the genome that was linked with the disease in all three families. That region was known to contain a gene for a protein called "factor H," as well as a number of other genes for proteins that are involved in the same pathway as factor H in controlling an ancient defence system called complement. This system helps antibodies to kill invaders by marking any cell that is not protected by proteins such as factor H. Our own cells would be under constant threat without protective proteins such as factor H. Later studies found simple genetic mutations in people with aHUS, in the genes coding for factor H. However, other work suggested that in some families with aHUS, simple genetic mutations might not be the cause; instead more complicated rearrangements of the genome might occur which would then result in an abnormal factor H that incorporated part of the gene for another protective protein called factor H related protein 1.
###end p 11
###begin title 12
Why Was This Study Done?
###end title 12
###begin p 13
###xml 321 327 <span type="species:ncbi:9606">people</span>
###xml 438 444 <span type="species:ncbi:9606">people</span>
The researchers knew that it was important to understand the exact genetic mutations linked with aHUS in different families. This was because the exact type of mutation would help them predict whether a kidney transplant is likely to be successful in treating an individual with aHUS who has developed kidney failure. In people with mutations affecting proteins produced by the kidney, a kidney transplant would be likely to work; but in people with mutations affecting factor H, which is produced by the liver, the disease would probably recur after a kidney transplant.
###end p 13
###begin title 14
What Did the Researchers Do and Find?
###end title 14
###begin p 15
In this study, the researchers went back to one of the three families with aHUS they had previously studied. The researchers had shown before that in this family, the disease was linked with the genome region containing factor H, but no precise mutation in that region had been found. This time, the researchers screened the genome of the family members and looked in particular for a specific rearrangement of the genome that they suspected might be involved. They found that the genomes in this family had been shuffled in the factor H region, resulting in an abnormal version of factor H being produced.
###end p 15
###begin title 16
What Do These Findings Mean?
###end title 16
###begin p 17
###xml 278 286 <span type="species:ncbi:9606">patients</span>
The mutation these researchers identified is likely to result in development of aHUS that does not get better after a kidney transplant, because the abnormal factor H would still be produced in the liver after a transplant had been done. Therefore, the researchers suggest that patients with aHUS be checked for this particular mutation before it is decided whether to go ahead with a transplant.
###end p 17
###begin title 18
Additional Information.
###end title 18
###begin p 19
Please access these Web sites via the online version of this summary at .
###end p 19
###begin p 20
 information about atypical hemolytic uremic syndrome
###end p 20
###begin p 21
###xml 75 80 <span type="species:ncbi:9606">human</span>
The  contains an entry on hemolytic uremic syndrome. OMIM is a database of human genes and genetic disorders developed by the US National Center for Biotechnology Information
###end p 21
###begin p 22
The  has a page about hemolytic uremic syndrome
###end p 22
###begin p 23
The  has a page about HUS (note that Wikipedia is a free online encyclopedia that anyone can edit)
###end p 23
###begin title 24
Introduction
###end title 24
###begin p 25
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b001">1</xref>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b001">1</xref>
###xml 844 845 844 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b002">2</xref>
Atypical HUS (aHUS) is characterised by the triad of a microangiopathic haemolytic anaemia (Coombs' test negative), thrombocytopenia, and acute renal failure in the absence of a preceding diarrhoeal illness. aHUS can be either sporadic or, if more than one member of a family is affected, familial. In 1998 we established linkage in three families with atypical haemolytic uraemic syndrome (aHUS) to a 26 cM region at chromosome location 1q32 [1]. This area contains a group of genes that play a pivotal role in the regulation of complement activation (the regulators of complement activation [RCA] cluster). In one of these families we found a mutation in the gene encoding the soluble regulator complement factor H [1] and subsequently in another we found a mutation in the gene encoding membrane cofactor protein, a transmembrane regulator [2]. In the third family extensive screening of genes within the RCA cluster failed to reveal an abnormality.
###end p 25
###begin p 26
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b003">3</xref>
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CFH)</italic>
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</italic>
###xml 208 215 208 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1&#8211;5</italic>
###xml 218 226 218 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g001">Figure 1</xref>
###xml 412 415 412 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b004">4</xref>
###xml 472 473 472 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b005">5</xref>
###xml 1170 1171 1170 1171 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</bold>
###xml 1175 1176 1175 1176 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 1184 1185 1184 1185 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1306 1307 1306 1307 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1311 1312 1311 1312 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1319 1320 1319 1320 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 1745 1746 1745 1746 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1753 1754 1753 1754 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</bold>
###xml 1849 1850 1849 1850 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</bold>
###xml 1857 1858 1857 1858 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2033 2034 2033 2034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b006">6</xref>
###xml 2035 2036 2035 2036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b008">8</xref>
###xml 2216 2217 2216 2217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b006">6</xref>
###xml 2218 2219 2218 2219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b009">9</xref>
Complement genes within the RCA cluster are arranged in tandem within two groups [3]. In a centromeric 360 kb segment lie the genes encoding factor H (CFH) and five factor H-related proteins-CFHL1-5 (aliases CFHR1-5) (Figure 1A). Sequence analysis of this region shows evidence of several large genomic duplications, also known as low copy repeats (LCRs), resulting in a high degree of sequence identity between CFH and the genes for the five factor H-related proteins [4,5]. The secreted protein products of these genes are similar in that they consist of repetitive units (~60 amino acids) named short consensus repeats (SCRs) or complement control protein modules. Each SCR is generally encoded by a single exon. CFH consists of 20 SCRs and CFHL1 consists of five. The highest degree of sequence identity is seen between SCRs 18 and 20 of CFH and SCRs 3 and 5 of CFHL1. CFH SCR 18 and CFHL1 SCR 3 consist of 59 amino acids. At the nucleotide level the exons encoding these two SCRs differ by five bases. Three result in an amino acid difference. CFH has tyrosine, valine, and glutamine residues at positions 1,058, 1,060, and 1,076, respectively (encoded by triplets TAT, GTG, and CAA), whilst CFHL1 has histidine, leucine, and glutamic acid residues at positions 157, 159, and 175 (encoded by triplets CAT, CTG and GAA). CFH SCR 19 and CFHL1 SCR 4 consist of 61 amino acids. The exons encoding these two SCRs differ at one nucleotide position, which does not result in a coding change. CFH SCR20 and CFHL1 SCR 5 consist of 67 amino acids. The exons differ at two nucleotide positions, both of which affect the amino acid sequence of the encoded proteins; CFH has serine and valine residues at positions 1,191 and 1,197 (encoded by triplets TCG and GTT) while CFHL1 has leucine and alanine residues at positions 290 and 296 (encoded by triplets TTG and GCT). Mutations reported in association with aHUS include c.3572C>T, which results in the change S1191L and c.3590T>C, which results in V1197A, either singly or in combination [6-8]. This raised the possibility that gene conversion of CFH SCR 20 by SCR 5 of CFHL1 is the mutational mechanism in a proportion of cases. c.3226C>G, Q1076E has also been reported [6,9], raising the possibility of gene conversion of CFH SCR 18 by SCR 3 of CFHL1.
###end p 26
###begin p 27
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b010">10</xref>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b011">11</xref>
###xml 543 551 543 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g001">Figure 1</xref>
###xml 590 598 590 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g001">Figure 1</xref>
###xml 604 605 604 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g001">1</xref>
###xml 663 666 663 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 671 676 671 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 689 694 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 699 704 699 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL3</italic>
###xml 831 834 831 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 839 845 839 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1,</italic>
###xml 866 871 866 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL3</italic>
###xml 897 906 897 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 983 991 983 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g001">Figure 1</xref>
###xml 1061 1064 1061 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1131 1136 1131 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 1183 1191 1183 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g001">Figure 1</xref>
###xml 1356 1358 1356 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b010">10</xref>
###xml 1397 1402 1397 1402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL3</italic>
###xml 1407 1412 1407 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 1435 1438 1435 1438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1460 1468 1460 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g001">Figure 1</xref>
###xml 1542 1547 1542 1547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 1552 1557 1552 1557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL3</italic>
###xml 1559 1567 1559 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g001">Figure 1</xref>
###xml 1650 1655 1650 1655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 1715 1717 1715 1717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b012">12</xref>
###xml 1798 1807 1798 1807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 1989 1990 1989 1990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b001">1</xref>
We recently reported two aHUS cases in which S1191L and V1197A changes occurred in combination as de novo events [10], thus providing unambiguous evidence that gene conversion is the mutational mechanism involved. LCRs such as those seen in the RCA cluster not only predispose to gene conversion events but are also associated with genomic rearrangements [11]. These rearrangements usually result from nonallelic homologous recombination between LCRs. If nonallelic recombination should occur between the duplicated segments B and B' shown in Figure 1B, a variety of products are possible (Figure 1C and 1D). If recombination occurred after the terminal exons of CFH and CFHL1 deletion of CFHL1 and CFHL3 would result. If recombination occurred within the region containing the three terminal exons (and their flanking introns) of CFH and CFHL1, then not only would CFHL3 be deleted, but a hybrid CFH/CFHL1 gene would be formed. If, for example, the recombination occurred at "X" in Figure 1B, a hybrid gene would result that consisted of the first 21 exons of CFH (encoding SCRs 1-18 of the hybrid gene) and the last two exons of CFHL1 (encoding SCRs 19 and 20 of the hybrid gene) (Figure 1C). The hybrid gene would encode a protein product identical to the aforementioned S1191L/V1197A mutant, a change that we have shown to be functionally significant [10]. If the recombination occurred at Y, CFHL3 and CFHL1 would be deleted, but CFH would remain intact (Figure 1C). The recombination event would also potentially lead to duplication of CFHL1 and CFHL3 (Figure 1D). There is already evidence that nonallelic recombination leading to deletion of CFHL1 occurs as a common polymorphism in the general population [12], and we here show that this phenomenon also leads to the formation of a hybrid CFH/CFHL1 gene associated with aHUS. In particular, we have shown the presence of such a hybrid gene in the affected members of the remaining unsolved family from our original linkage study [1].
###end p 27
###begin title 28
Methods
###end title 28
###begin title 29
Clinical Details and Informed Consent
###end title 29
###begin p 30
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b013">13</xref>
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b001">1</xref>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b001">1</xref>
###xml 265 273 265 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g002">Figure 2</xref>
The family that is the subject of our study was first reported in 1975 [13] and more recently in 1998 [1]. This is the aforementioned one remaining unsolved family from our original linkage study in three aHUS families in 1998 [1]. The current pedigree is shown in Figure 2. Affected member I:2 died at the age of 57 y, 7 d after presenting with pericarditis, heart failure, and hypertension.
###end p 30
###begin p 31
II:1 presented with the classical features of HUS at the age of 45 y, following a 9 mo history of hypertension. Serum complement levels were normal. Renal function did not recover and haemodialysis was commenced. Bilateral nephrectomy was undertaken because of ongoing haemolysis and severe hypertension. He subsequently received two renal transplants, one at the age of 46 y and the other at 49 y. Both kidneys were lost to "acute rejection," the first after 18 mo and the second after 8 mo. In retrospect the clinical and histopathological features were compatible with recurrent HUS. He died of a myocardial infarct at the age of 55 y.
###end p 31
###begin p 32
II:2, the twin brother of II:1, presented at the age of 46 y with acute renal failure and hypertension. Investigations were compatible with a diagnosis of HUS. As with his brother, bilateral nephrectomy was necessary to control ongoing haemolysis and hypertension. He subsequently received two transplants, one at the age of 47 y and the other at 60 y. Both kidneys were lost within weeks of transplantation due to recurrent HUS. II:7 and II:10 both died of acute renal failure. II:8 died at the age of 82 y without any evidence of renal disease.
###end p 32
###begin p 33
III:3 is currently aged 53 y and is well. Complement profiles have shown a persistently borderline low C3. III:4 presented at the age of 19 y with a grand mal convulsion. She had started an oral contraceptive 6 wk previously. Investigations were consistent with HUS. A complement profile was said to be normal. She died 8 wk after presentation following cardiac arrest. III:5 presented with HUS at the age of 5 y and died 6 d after presentation. III:6 presented at the age of 28 y with a short history of headaches and lethargy. Investigations were compatible with a diagnosis of HUS. He has remained on haemodialysis since then and is currently well. III:8 presented at the age of 7 y with fluid retention, hypertension, and acute renal failure. He died 9 d after admission.
###end p 33
###begin p 34
IV:1 presented at the age of 7 y with HUS following a viral illness. Despite treatment with peritoneal dialysis, plasma exchange, and prostacyclin, he did not recover renal function. He received a cadaver renal transplant at age 16 y, which, despite daily plasma exchange, was lost to recurrent HUS within the first two postoperative weeks. He was subsequently treated with both peritoneal dialysis and haemodialysis. He died suddenly at the age of 22 y.
###end p 34
###begin p 35
Mutation screening of the genes for factor H, membrane cofactor protein, and factor I in this family had not revealed any abnormalities.
###end p 35
###begin p 36
The study was approved by the Northern and Yorkshire Multi-Centre Research Ethics Committee and informed consent obtained.
###end p 36
###begin title 37
Complement Assays
###end title 37
###begin p 38
Convalescent EDTA plasma samples were obtained and stored at -80 degreesC. C3 and C4 levels were measured by rate nephelometry (Beckman Array 360; Beckman, Fullerton, California, United States). Factor H levels were measured by radioimmunodiffusion (Binding Site, Birmingham, UK).
###end p 38
###begin title 39
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
CFH Genomic DNA Sequencing
###end title 39
###begin p 40
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 60 61 60 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b006">6</xref>
CFH gDNA sequencing was undertaken as previously described [6] apart from exon 23, where the primers used were: forward 5'-CCTAATTCTCATACATTAAACATCG-3' and reverse 5'-CAACCGTTAGTTTTCCAGGA-3'. All primers incorporated a 5' "UNISEQ" M13-derived 17 bp tail that allowed subsequent sequencing using a common forward (5'-GTAGCGCGACGGCCAGT-3') and reverse (5'-CAGGGCGCAGCGATGAC-3') primer. PCR products were purified using magnetic microparticles (AMPure, Beckman) to remove unincorporated dNTPs, primers, and salts. Sequencing reactions were carried out by dye terminator cycle sequencing (DTCS kit, Beckman) using UNISEQ primers, purified using magnetic microparticles (CleanSeq, Beckman), and electrophoresed on a fluorescent 16 capillary sequencer (Beckman CEQ 8000).
###end p 40
###begin p 41
###xml 38 41 38 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 308 313 308 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b014">14</xref>
The reference nucleotide sequence for CFH was taken from GenBank RefSeq () file NM_000186.1, and the nucleotide numbering uses the A of the ATG translation initiation start site as nucleotide +1. The factor H amino acid numbering includes the 18-residue signal peptide. The reference nucleotide sequence for CFHL1 was taken from Genbank RefSeq file NM_002113.1, and the nucleotide numbering uses the A of the ATG translation initiation start site as nucleotide +1. CFH exons have been numbered 1-23 according to Rodriguez de Cordoba et al. [14]. In this nomenclature, exon 10 contributes to the transcript for factor H-like protein 1 but not factor H. The factor H-related protein 1 amino acid numbering includes the 18-residue signal peptide.
###end p 41
###begin title 42
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
CFH cDNA Sequencing
###end title 42
###begin p 43
###xml 23 26 23 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 28 36 28 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g003">Figure 3</xref>
###xml 202 205 202 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 300 303 300 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 368 373 368 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 431 434 431 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 449 454 449 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 456 464 456 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g003">Figure 3</xref>
For cDNA sequencing of CFH (Figure 3) mRNA was extracted from peripheral blood lymphocytes of family members (affected and unaffected) and unrelated controls. cDNA was prepared in a standard manner and CFH exons 21-23 amplified by seminested PCR. The forward primers were designed to be specific for CFH and were therefore sited in exon 20, which is not homologous to CFHL1. The reverse primer was complementary to both exon 23 of CFH and exon 6 of CFHL1 (Figure 3A). The first-round forward primer was 5'-GCCATACCCATGGGAGAGAAGA-3' and the second-round forward primer was 5'-CGGGTGAGCAAGTGACTTACACT-3'. The reverse primer for both rounds was 5'-GGATACTCCAGTTTCCCATCCCA-3'. Each primer incorporated a "UNISEQ" tail as before to enable sequencing with UNISEQ primers.
###end p 43
###begin title 44
###xml 50 59 50 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
Identification and Screening of the Breakpoint in CFH/CFHL1 Hybrid Gene
###end title 44
###begin p 45
###xml 39 47 39 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g004">Figure 4</xref>
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 145 154 145 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 194 197 194 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 212 217 212 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
To identify and screen the breakpoint (Figure 4), first we amplified genomic DNA across the intron between exons 21 and 22 (CFHL1 exon 5) of the CFH/CFHL1 hybrid gene using primers specific for CFH (forward) and CFHL1 (reverse) sequence.
###end p 45
###begin p 46
###xml 173 181 173 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g004">Figure 4</xref>
###xml 206 209 206 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
Next, we screened the identified breakpoint in the affected family using the primer pair 5'-CCATCTGGTGAGAGAGTACGTT-3' (forward) and 5'-ACCCAGGACTATGTGCTCGGACT-3' (reverse) (Figure 4B), which anneal to both CFH and CFHL1. Each primer incorporated a "UNISEQ" tail as before to enable sequencing with UNISEQ primers.
###end p 46
###begin title 47
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
CFH Dosage Analysis by Quantitative Fluorescent PCR
###end title 47
###begin p 48
###xml 80 83 80 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 188 189 187 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 295 296 294 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 297 298 296 297 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 300 301 299 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 606 610 575 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 623 628 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 788 795 757 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030431-t001">Table 1</xref>
Two multiplex PCR assays were designed to simultaneously amplify exons 20-23 of CFH. PCRs were carried out in 25 mul volumes using 150 ng of DNA and contained 0.5 mM each dNTP, 6.7 mM MgCl2, 12.5 pmol of each primer, 1 U of a hot start Taq polymerase (Immolase, Bioline) in a buffer of 16 mM (NH4)2SO4, 67 mM Tris-HCl, 0.01% Tween-20. PCR cycling conditions were such that amplification remained in the linear phase of the reaction (95degreesC for 7 min; 20 cycles of: 94 degreesC for 45 s, 60 degreesC for 45 s, 72 degreesC for 1 min; and a final extension of 10 min at 72 degreesC). Primers that amplify MLH1 exon 14 and BRCA1 exon 16 were included in the assay as controls for normal dosage. One of each pair of primers was fluorescently labelled (5'FAM), and all primers are shown in Table 1. After PCR amplification products were analysed by capillary electrophoresis (ABI, Perkin Elmer). Peak areas were obtained for each sample and dosage quotients calculated.
###end p 48
###begin title 49
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
CFH Multiplex Ligation-Dependent Probe Amplification
###end title 49
###begin p 50
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b015">15</xref>
###xml 274 277 274 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 315 319 315 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 331 335 331 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 493 501 493 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g005">Figure 5</xref>
###xml 506 513 506 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030431-t002">Table 2</xref>
The multiplex ligation-dependent probe amplification (MLPA) reaction has been described [15]. In this study a completely synthetic probe set was used, obviating the need for a cloning step in the production of probes. Probes were designed to determine dosage for a range of CFH exons, along with control probes for MSH2 exon 1 and MLH1 exon 19 (NM_000251, NM_000249). Each probe pair hybridises to immediately adjacent targets at the sequence of interest. Hybridisation sequences are shown in Figure 5 and Table 2. Probe pairs also contained binding sites for primers used in the MLPA reaction, as well as stuffer sequence to ensure that each amplified probe product is of a unique length. Oligonucleotides were obtained from TAG Newcastle Limited (Gateshead, UK [now available at VH Bio: ]). 5' probes were RP-column purified. 3' probes were 5'-phosphorylated and purified by desalting.
###end p 50
###begin p 51
###xml 770 771 767 768 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Reagents for the MLPA reaction were purchased from MRC-Holland (Amsterdam, the Netherlands). The ligation reactions were carried out according to the manufacturer's recommended protocol using 100-200 ng of genomic DNA and 2 fmol of probe. Incubations and PCR amplifications were carried out on a DNA Engine Tetrad 2 thermal cycler (BioRad Laboratories, Hercules, California, United States). Amplified products were diluted 1 in 10 to give peak heights within the quantitative range (approximately 100-4,000 units) on the ABI PRISM 3130 Genetic Analyzer capillary electrophoresis system (Applied Biosystems, Foster City, California, United States). For size standards, 1 mul of diluted product and 0.5 mul of ROX 500 internal size standard were made up to 10 mul using dH2O, and samples were run on the ABI 3130. Peak areas for each sample were determined using the proprietary Genemapper software and dosage quotients calculated.
###end p 51
###begin title 52
Southern Blots
###end title 52
###begin p 53
###xml 84 93 84 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 137 140 137 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 221 229 221 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g006">Figure 6</xref>
###xml 287 296 287 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 400 403 400 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 415 420 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
To provide further confirmation that the point of recombination responsible for the CFH/CFHL1 hybrid gene lies within the intron between CFH exons 21/22 and CFHL1 exons 4/5, Southern blots were done using a 1.1 kb probe (Figure 6). The putative crossover leading to the formation of the CFH/CFHL1 hybrid gene is shown as a line that crosses over 110-150 bases into the introns between exons 21/22 of CFH and 4/5 of CFHL1. A DNA probe was prepared by PCR amplification of a 1.1 kb region spanning the putative breakpoint using the following primers: forward, 5'-GTAGCGCGACGGCCAGTGGTCTATCAGTGTTCTAGCGAAGGA-3' and reverse, 5'-GTGCACCAGTTAACAGGCCAT-3'.
###end p 53
###begin p 54
###xml 133 138 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
Genomic DNA (10 mug) from two affected individuals, one unaffected individual, and two individuals who were homozygously deleted for CFHL1 was digested with HindIII. Electrophoresis was carried out overnight in a 0.8% agarose gel in 1x TAE buffer (0.04 M Tris-acetate buffer, 0.001 M EDTA) at 40 mA. DNA was transferred to a nylon membrane (Hybond N+, Amersham []) after denaturation in 1.5 M NaCl, 0.5 M NaOH and neutralisation in 0.4 M Tris base, 0.25 M trisodium citrate, 2.5 M NaCl. The DNA probe (20 ng) was labelled using the Rediprime system (Amersham). Hybridisations were carried out overnight at 65 degreesC in a mix containing 5x SSC (0.75 M NaCl, 0.075 M trisodium citrate), 5x Denhardt's (0.1% PVP, 0.1% BSA, and 0.1% Ficoll), 0.1% SDS, 0.1% sodium pyrophosphate, 10% dextran sulfate, and 100 mug/ml sonicated denatured salmon sperm DNA. The filter was washed at 65 degreesC to a final stringency of 0.5x SSC (including 0.1% SDS) and autoradiographed with intensifying screens for 12 h.
###end p 54
###begin title 55
Results
###end title 55
###begin title 56
Complement Profiles
###end title 56
###begin p 57
###xml 50 57 50 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030431-t003">Table 3</xref>
Serum levels of C3, C4, and factor H are shown in Table 3. Factor H levels were normal in all family members, as was expected, because the secreted product of the hybrid gene is identical to the factor H mutant c.3572C>T, S1191L/c.3590T>C, V1197A.
###end p 57
###begin title 58
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
CFH gDNA Sequencing
###end title 58
###begin p 59
###xml 22 25 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 232 241 232 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 313 316 313 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
Sequencing of genomic CFH DNA from II:8 (unaffected carrier), III:1 (unaffected), III:3 (unaffected carrier), III:6 (affected), III:7 (unaffected) and IV:1 (affected) showed wild-type sequence. This was expected, because the hybrid CFH/CFHL1 gene described here would not be picked up by genomic sequencing using CFH-specific primers
###end p 59
###begin title 60
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
CFH cDNA Sequencing
###end title 60
###begin p 61
###xml 180 188 180 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g003">Figure 3</xref>
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g003">3</xref>
In III:3 (unaffected carrier) and III:6 (affected), cDNA sequencing showed two heterozygous changes c.3572C>T and c.3590T>C in exon 23, leading to S1191L and V1197A, respectively (Figure 3B and 3C). In addition, there was a heterozygous synonymous change in exon 22. These changes were not found in III:1, III:7 (both unaffected), or an unrelated control.
###end p 61
###begin title 62
###xml 54 63 54 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
Identification and Screening of the Breakpoint in the CFH/CFHL1 Hybrid Gene
###end title 62
###begin p 63
###xml 96 99 96 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 183 188 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 204 213 204 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 411 414 411 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 419 424 419 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 435 443 435 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g004">Figure 4</xref>
###xml 550 553 550 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 565 573 565 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g004">Figure 4</xref>
###xml 627 635 627 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g004">Figure 4</xref>
###xml 676 685 676 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 702 707 702 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
The DNA breakpoint in III:6 (affected) was identified by sequencing PCR products using specific CFH (forward) and CFHL1 (reverse) primers spanning the intron between exons 21 and 22 (CFHL1 exon 5) of the CFH/CFHL1 hybrid gene. This generated a unique product, sequencing of which showed the breakpoint to be in a 52 bp section starting 118 bp into intron 21. The 52 bp section is defined by differences between CFH and CFHL1 sequence (Figure 4A). Screening of other family members using primers spanning the breakpoint and designed to anneal to both CFH and CFHL1 (Figure 4B) confirmed the breakpoint. Sequence of this region (Figure 4C) shows a switch from heterozygosity at CFH/CFHL1 unique bases to CFHL1 sequence in III:3 (unaffected carrier) and III:6 (affected) compared with III:1 (unaffected), III:7 (unaffected), and a normal unrelated control.
###end p 63
###begin title 64
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
CFH Dosage Analysis by Quantitative Fluorescent PCR and MLPA
###end title 64
###begin p 65
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 67 70 67 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 260 268 260 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g007">Figure 7</xref>
CFH dosage quotients showed an apparent heterozygous "deletion" of CFH exons 22 and 23 in II:8 (unaffected carrier), III:3 (unaffected carrier), III:6 (affected), and IV:1 (affected). There was no evidence of a "deletion" in III:1 and III:7 (both unaffected) (Figure 7).
###end p 65
###begin p 66
###xml 111 114 111 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 178 181 178 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 260 269 260 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 292 295 292 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
In a panel of 80 patients with aHUS, three further individuals were identified by MLPA as having a deletion of CFH exons 22 and 23. In all three, factor H levels were normal and CFH gDNA sequencing had shown normal wild-type sequence, but presence of a hybrid CFH/CFHL1 gene was confirmed by CFH cDNA sequencing. This showed the same changes identified in III:3 and III:6.
###end p 66
###begin p 67
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
In a panel of 100 normal control individuals, MLPA showed no evidence of a deletion of CFH exons 22 and 23.
###end p 67
###begin title 68
Southern Blot
###end title 68
###begin p 69
###xml 134 142 134 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g006">Figure 6</xref>
###xml 194 203 194 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 221 229 221 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g006">Figure 6</xref>
In III:3 (unaffected carrier) and III:6 (affected) a Southern blot with HindIII showing an additional 8.6 kb band (the band at "B" in Figure 6B). This additional band is derived from the hybrid CFH/CFHL1 gene as shown in Figure 6A.
###end p 69
###begin title 70
Discussion
###end title 70
###begin p 71
###xml 158 167 158 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b010">10</xref>
###xml 541 550 541 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 678 679 678 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b001">1</xref>
###xml 1223 1228 1223 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 1340 1342 1340 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b012">12</xref>
###xml 1408 1413 1408 1413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 1462 1471 1462 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 1707 1710 1707 1710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1833 1835 1833 1835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b016">16</xref>
###xml 1892 1895 1892 1895 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1953 1962 1953 1962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 2034 2037 2034 2037 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 2131 2134 2131 2134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1607 1615 <span type="species:ncbi:9606">patients</span>
###xml 1691 1699 <span type="species:ncbi:9606">patients</span>
###xml 1875 1883 <span type="species:ncbi:9606">patients</span>
###xml 2100 2108 <span type="species:ncbi:9606">patients</span>
In this study we have provided conclusive evidence that LCR nonhomologous recombination in the RCA cluster of genes has resulted in the formation of a hybrid CFH/CFHL1 gene that predisposes to the development of aHUS. The protein product of the hybrid gene is identical to the factor H mutant c.3572C>T, S1191L/c.3590T>C, V1197A which we have shown arises by gene conversion in aHUS [10]. We have previously shown that this mutant is functionally significant, in that binding to C3b is impaired. The hypothesis for the existence of a hybrid CFH/CFHL1 gene in the family described in this manuscript was based on two observations. First, we knew from our original linkage study [1] that the affected individuals in this family mapped to the RCA cluster at position 1q32. Moreover, in this family there was a strong history of disease recurrence following kidney transplantation, suggesting that a soluble circulating complement regulator was responsible. Second, our recent observation that LCRs in the RCA cluster predisposed to gene conversion events suggested that LCR nonhomologous recombination might also be occurring. In support of this was the observation that the presence of factor H-related protein 1 (encoded by CFHL1) in the serum of normal controls is polymorphic, with 4.4% of healthy blood donors having complete deficiency [12]. We hypothesised that the crossover responsible for deletion of CFHL1 could also potentially result in formation of a CFH/CFHL1 hybrid gene. The evidence presented here strongly supports this hypothesis. Moreover, we have evidence from three other unrelated aHUS patients that the phenomenon is not unique to this family. Renal transplantation in patients with a CFH mutation is associated with an 80% risk of the graft being lost to recurrent disease within two years of transplantation [16]. It is currently recommended that all patients undergo CFH genotyping prior to transplantation. However, the hybrid CFH/CFHL1 gene described here would not be picked up by genomic sequencing using CFH-specific primers. We would, therefore, now recommend that all patients be screened also with CFH MLPA.
###end p 71
###begin p 72
###xml 149 152 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b017">17</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b020">20</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b021">21</xref>
###xml 363 368 363 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL3</italic>
Could the results of this study have implications for other complement-related diseases? It has been established in several independent cohorts that CFH alleles act as a susceptibility factor for age-related macular degeneration [17-20] and type II membranoproliferative glomerulonephritis [21]. It would be fascinating to test the hypothesis that copy number of CFHL1 and CFHL3 acts as a susceptibility factor for such diseases. It is tempting to speculate that such an effect might be mediated by an interaction between factor H and the factor H-related proteins.
###end p 72
###begin title 73
Supporting Information
###end title 73
###begin title 74
Accession Numbers
###end title 74
###begin p 75
###xml 131 134 131 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 145 150 145 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL2</italic>
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL3</italic>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL4</italic>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL5</italic>
###xml 292 296 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 320 324 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 32 35 <span type="species:ncbi:9606">Man</span>
Online Mendelian Inheritance in Man () accession numbers for the genes and conditions discussed in this article are aHUS (235400), CFH (134370), CFHL1 (134371), CFHL2 (600889), CFHL3 (605336), CFHL4 (OMIM 605337), and CFHL5 (OMIM 608593). The GenBank () accession numbers for other genes are MSH2 exon 1 (NM_000251) and MLH1 exon 19 (NM_000249).
###end p 75
###begin title 76
Abbreviations
###end title 76
###begin p 77
atypical haemolytic uraemic syndrome
###end p 77
###begin p 78
low copy repeat
###end p 78
###begin p 79
multiplex ligation-dependent probe amplification
###end p 79
###begin p 80
regulator of complement activation
###end p 80
###begin p 81
short consensus repeat
###end p 81
###begin title 82
References
###end title 82
###begin article-title 83
Genetic studies into inherited and sporadic haemolytic uraemic syndrome
###end article-title 83
###begin article-title 84
###xml 13 18 <span type="species:ncbi:9606">human</span>
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome
###end article-title 84
###begin article-title 85
A radiation hybrid map of complement factor H and factor H-related genes
###end article-title 85
###begin article-title 86
###xml 92 101 92 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fH, fHR-1</italic>
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fHR-3</italic>
###xml 52 57 <span type="species:ncbi:9606">human</span>
Complement factor H: Sequence analysis of 221 kb of human genomic DNA containing the entire fH, fHR-1 and fHR-3 genes
###end article-title 86
###begin article-title 87
The factor H protein family
###end article-title 87
###begin article-title 88
Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition
###end article-title 88
###begin article-title 89
Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome
###end article-title 89
###begin article-title 90
The molecular basis of familial hemolytic uremic syndrome: Mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20
###end article-title 90
###begin article-title 91
Haemolytic uraemic syndrome and mutations of the factor H gene: A registry-based study of German speaking countries
###end article-title 91
###begin article-title 92
De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome
###end article-title 92
###begin article-title 93
Genomic disorders: Molecular mechanisms for rearrangements and conveyed phenotypes
###end article-title 93
###begin article-title 94
###xml 31 36 <span type="species:ncbi:9606">human</span>
Polymorphism and deficiency of human factor H-related proteins p39 and p37
###end article-title 94
###begin article-title 95
The haemolytic uraemic syndrome-A family study
###end article-title 95
###begin article-title 96
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human complement factor H: Functional roles, genetic variations and disease associations
###end article-title 96
###begin article-title 97
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification
###end article-title 97
###begin article-title 98
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Outcome of renal transplantation in patients with non-shiga toxin-associated hemolytic uremic syndrome: Prognostic significance of genetic background
###end article-title 98
###begin article-title 99
Complement factor H polymorphism and age-related macular degeneration
###end article-title 99
###begin article-title 100
Complement factor H variant increases the risk of age-related macular degeneration
###end article-title 100
###begin article-title 101
Complement factor H polymorphism in age-related macular degeneration
###end article-title 101
###begin article-title 102
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration
###end article-title 102
###begin article-title 103
Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)
###end article-title 103
###begin title 104
Figures and Tables
###end title 104
###begin title 105
Genomic Structure of the Region of the RCA Cluster Containing the Genes Encoding Factor H and the Five factor H-Related Proteins
###end title 105
###begin p 106
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b004">4</xref>
Genomic duplications including the different exons of the six genes were originally determined by Male et al. [4] and are colour-coded. Exons are indicated as vertical lines.
###end p 106
###begin p 107
(A) Position of the genes encoding factor H and the factor H-related proteins in a centromeric segment of the RCA cluster at 1q32.
###end p 107
###begin p 108
###xml 119 122 119 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 187 192 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 307 312 307 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL3</italic>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 327 330 327 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
(B and C) Nonhomologous recombination occurring at X would result in a hybrid gene consisting of the first 21 exons of CFH (encoding SCRs 1-18 of the hybrid gene) and the last 2 exons of CFHL1 (encoding SCRs 19 and 20 of the hybrid gene). If the recombination occurred at Y this would result in deletion of CFHL3 and CFHL1 but CFH would remain intact.
###end p 108
###begin p 109
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL3</italic>
(D) The recombination event would also potentially lead to a duplication of CFHL1 and CFHL3.
###end p 109
###begin p 110
###xml 21 29 21 29 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030431-g001">Figure 1</xref>
###xml 34 36 34 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030431-b015">15</xref>
###xml 62 67 <span type="species:ncbi:9606">Human</span>
(Figure adapted from Figure 1 of [15] with kind permission of Human Mutation C 2006, Wiley Liss Inc., A Wiley Company.)
###end p 110
###begin title 111
Pedigree of the Family
###end title 111
###begin title 112
cDNA Evidence of a Hybrid Gene
###end title 112
###begin p 113
###xml 13 16 13 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 221 224 221 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
(A) Inverted CFH exons 20-23 cDNA sequence showing the site of the first-round forward primers (blue), the second round forward primers (green), and the reverse primers for both rounds (red). The nucleotides at which the CFH and CFHL1 sequences differ are shown in bold and highlighted (excluding exon 20).
###end p 113
###begin p 114
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 112 121 112 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 151 154 151 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 159 164 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 330 333 330 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
(B) Inverted cDNA sequence of CFH exons 20-23 from III:6 (affected family member) showing evidence for a hybrid CFH/CFHL1 gene. Positions at which the CFH and CFHL1 sequences differ are indicated by arrows. At the three differences in exons 22 and 23 (numbered 1-3) there is a heterozygous base change, one allele being wild-type CFH and the other the equivalent base from CFHL1.
###end p 114
###begin p 115
###xml 42 51 42 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 174 177 174 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
(C) Inverted cDNA sequence showing hybrid CFH/CFHL1 sequence (c.3590T>C, V1197A, and c.3572C>T, S1191L) in III:6 (affected) and III:3 (unaffected carrier) compared to normal CFH sequence in III:1 (unaffected), III:7 (unaffected), and a normal unrelated control.
###end p 115
###begin title 116
Identifying and Screening the Breakpoint Region
###end title 116
###begin p 117
###xml 59 62 59 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 164 167 164 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
(A) Sequence of unique PCR product generated with specific CFH (forward) and CFHL1 (reverse) primers from III:6 (affected) demonstrating the hybrid product. Unique CFH positions are indicated with black arrows, and unique CFHL1 nucleotides are indicated with red arrows.
###end p 117
###begin p 118
###xml 28 31 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
(B) The genomic sequence of CFH is shown aligned above CFHL1. Exons 21 and 4 of the two genes respectively are highlighted in grey. The primer-binding sites for the PCR are shown in red. The differences visible in intron 21/4 from sequencing the product are highlighted in the standard base colours A (green), C (blue), G (black), and T (red). The breakpoint is within the region underlined.
###end p 118
###begin p 119
###xml 89 98 89 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
(C) Sequence of the intron between exons 21 and 22 shows a switch from heterozygosity at CFH/CFHL1 unique bases to a CFHL1 sequence in III:3 (unaffected carrier) and III:6 (affected) compared with III:1 (unaffected), III:7 (unaffected), and a normal unrelated control.
###end p 119
###begin title 120
###xml 49 52 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
MLPA Binding Sites Used to Identify Deletions of CFH Exons 22 and 23
###end title 120
###begin p 121
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
The hybridisation sequence for the 5' and 3' probes are shown by red and blue, respectively. The genomic sequence of CFH is shown aligned above CFHL1.
###end p 121
###begin title 122
Southern Blot Evidence of Genomic Rearrangement
###end title 122
###begin p 123
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH,</italic>
###xml 197 203 197 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1,</italic>
###xml 222 231 222 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHL1</italic>
(A) A Southern blot using a 1.1 kb probe overlying CFH exon 21 and CFHL1 exon 4 hybridised to HindIII-digested DNA (sites shown as arrows) will result in fragments of 11.2 kb from CFH, 1.4 kb from CFHL1, and 8.6 kb from a CFH/CFHL1 hybrid gene. The site of the 1.1 kb probe is indicated above.
###end p 123
###begin p 124
###xml 261 266 261 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1</italic>
###xml 321 324 321 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 341 347 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHL1,</italic>
(B) Southern blot showing an additional 8.6 kb band (indicated by B) in lanes 2 and 3, which represent III:3 (unaffected carrier) and III:6 (affected) compared to lanes 1, 4, and 5, which represent III:1 (unaffected) and individuals with homozygous deletion of CFHL1. Bands at A and C represent fragments of 11.2 kb from CFH and 1.4 kb from CFHL1, respectively. A size ladder is shown to the right with heavy arrows indicating the expected sizes.
###end p 124
###begin title 125
Dosage Evidence of a Hybrid Gene
###end title 125
###begin p 126
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
(A) QF-PCR and (B) MLPA dosage quotients showed an apparent heterozygous "deletion" of CFH exons 22 and 23 in II:8 (unaffected carrier), III:3 (unaffected carrier), III:6 (affected), and IV:1 (affected). There was no evidence of a "deletion" in III:1 and III:7 (both unaffected).
###end p 126
###begin p 127
###xml 25 28 25 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
Primer Sequences for the CFH QF-PCR Dosage Analysis
###end p 127
###begin p 128
###xml 32 35 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
Hybridisation Sequences for the CFH Exons 22/23 MLPA Probes
###end p 128
###begin p 129
Complement Levels
###end p 129
###begin p 130
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 130
###begin p 131
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. JPV, LS, DR, MSJ, AH, JAG, and THJG designed the study. DB, HMP, MLDT, and AS contributed to the laboratory analyses. PW, PM, MW, and YP collected clinical information. JPV, LS, DR, DB, HMP, PW, MLDT, AS, MSJ, KMW, JAG, and THJG contributed to writing the paper.
###end p 131
###begin p 132
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
###xml 111 119 <span type="species:ncbi:9606">Children</span>
Funding: This work was supported by grants from the Northern Counties Kidney Research Fund, the Foundation for Children with Atypical HUS, and the Robin Davies Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 132

